

CITATION REPORT

List of articles citing

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

DOI: 10.1111/bcp.14889

British Journal of Clinical Pharmacology, 2021, , .

Source: <https://exaly.com/paper-pdf/80392786/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
78	Emerging epigenetic targets in rheumatoid arthritis. <i>Rheumatology International</i> , 2021 , 41, 2047-2067	3.6	2
77	Effects of 4-Hexylresorcinol on Craniofacial Growth in Rats. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
76	Enhancers in disease: molecular basis and emerging treatment strategies. <i>Trends in Molecular Medicine</i> , 2021 , 27, 1060-1073	11.5	4
75	Vorinostat (SAHA) and Breast Cancer: An Overview. <i>Cancers</i> , 2021 , 13,	6.6	7
74	Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives. <i>Trends in Pharmacological Sciences</i> , 2021 , 42, 829-844	13.2	2
73	Epigenetic modifications in diabetes. <i>Metabolism: Clinical and Experimental</i> , 2022 , 126, 154920	12.7	3
72	Deacetylation of Transcription Factors in Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
71	Histone deacetylase inhibition improves metabolism and mitochondrial dynamics: A potential novel therapeutic strategy for sarcopenia coexisting with diabetes mellitus. <i>Medical Hypotheses</i> , 2021 , 158, 110724	3.8	0
70	Epigenetics of childhood trauma: Long term sequelae and potential for treatment. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 ,	9	1
69	Kidney cell type specific changes in the chromatin and transcriptome landscapes following epithelial Hdac1 and Hdac2 knockdown. <i>Physiological Genomics</i> , 2021 ,	3.6	0
68	Selected Histone Deacetylase Inhibitors Reverse the Frataxin Transcriptional Defect in a Novel Friedreich's Ataxia Induced Pluripotent Stem Cell-Derived Neuronal Reporter System.. <i>Frontiers in Neuroscience</i> , 2022 , 16, 836476	5.1	0
67	HDAC inhibition as neuroprotection in COVID-19 infection.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	0
66	Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease.. <i>FEBS Journal</i> , 2022 ,	5.7	0
65	Emerging Role of HDACs in Regeneration and Ageing in the Peripheral Nervous System: Repair Schwann Cells as Pivotal Targets.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
64	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
63	Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	
62	Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.. <i>Brain, Behavior, and Immunity</i> , 2022 , 102, 151-160	16.6	1

61	Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.. <i>Cancers</i> , 2021 , 14,	6.6	4
60	New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 863677	5.6	1
59	AI Egen based turn-on fluorescent probes of histone deacetylase 6 via restriction of molecular motion. <i>Sensors and Actuators B: Chemical</i> , 2022 , 364, 131882	8.5	0
58	Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1934-1945	5.6	0
57	Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1/XBP1 pathway.. <i>Journal of Zhejiang University: Science B</i> , 2022 , 23, 392-406	4.5	
56	Design, Synthesis and Cytotoxic Activity Evaluation of Newly Synthesized Amides-Based TMP Moiety as Potential Anticancer Agents over HepG2 Cells. <i>Molecules</i> , 2022 , 27, 3960	4.8	1
55	Targeting cellular senescence to combat cancer and ageing. <i>Molecular Oncology</i> ,	7.9	0
54	BET-ting on histone proteomics in schizophrenia. <i>Trends in Neurosciences</i> , 2022 ,	13.3	0
53	HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells. 2022 , 23, 8645		0
52	Valproate Adjuvant Cognitive Behavioral Therapy in Panic Disorder Patients With Comorbid Bipolar Disorder: Case Series and Review of the Literature. 2022 , 19, 614-625		
51	Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling. 9,		0
50	Current trends in development of HDAC-based chemotherapeutics. 2022 , 308, 120946		0
49	Combination Epigenetic Therapy. 2023 , 821-840		0
48	Epigenetics of Brain Disorders. 2023 , 737-759		0
47	In vitro and in vivo anti-toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis. 12,		0
46	HDAC1 overexpression alters GTPase activity impacting chemoresistance in pancreatic cancer.		0
45	A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. 2022 , 23, 10014		0
44	Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization. 2022 ,		0

43	Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. 2022 , 23, 10211	0
42	Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. 9,	1
41	Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.	0
40	Molecular targeted therapy for anticancer treatment.	1
39	Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors. 2022 , 15, 1260	0
38	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. 2022 , 108301	0
37	HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode. 2022 , 129, 106181	0
36	Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. 2023 , 475, 214899	0
35	Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?. 2022 , 14, 5472	0
34	Discovery of novel HDAC8 inhibitors from natural compounds by in silico high throughput screening. 1-11	0
33	A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma.	0
32	Implications of cancer stem cells in diabetes and pancreatic cancer. 2022 , 121211	0
31	Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. 2022 , 14, 5926	0
30	Selective HDAC6 inhibition has the potential for anti-cancer effect in renal cell carcinoma.	0
29	Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies. 2023 , 15, 138	0
28	Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity. 2022 , 102800	1
27	Expanding the HDAC druggable landscape beyond enzymatic inhibition.	0
26	Azumamides A-E: Isolation, Synthesis, Biological Activity, and Structure-Activity Relationship. 2022 , 27, 8438	0

25	NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.	0
24	Epigenetics in Cancer Biology. 2022 ,	0
23	Zingiberene, a non-zinc-binding class I HDAC inhibitor: a novel strategy for the management of neuropathic pain. 2023 , 154670	1
22	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. 2023 ,	0
21	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. 2023 , 30,	1
20	Histone Modifications in Alzheimer's Disease. 2023 , 14, 347	0
19	Novel (E)-3-(1-substituted-1H-indazol-5-yl)-N-hydroxypropenamides as histone deacetylase inhibitors: design, synthesis and structure-activity relationships.	0
18	Development of LpxH inhibitors chelating the active site di-manganese metal cluster of LpxH.	0
17	2-Aminobenzothiazoles in anticancer drug design and discovery. 2023 , 135, 106477	0
16	Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy. 2023 , 16, 227	0
15	Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas. 2022 , 30, 211-219	0
14	Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations.	0
13	Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. 2023 , 73-161	0
12	The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors. 2023 , 28, 1973	0
11	Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. 2023 , 24, 4306	0
10	HDACs as an emerging target in endocrine tumors: a comprehensive review. 2023 , 18, 143-154	0
9	Ultrasound-Activatable g-C ₃ N ₄ -Anchored Titania Heterojunction as an Intracellular Redox Homeostasis Perturbator for Augmented Oncotherapy. 2300244	0
8	Transcriptional and Epigenetic Regulation of Context-Dependent Plasticity in T-Helper Lineages. 2023 , 23,	1

- 7 The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. **2023**, 559, 216121
- 6 Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. 14,
- 5 Recent research progress on small molecule compounds and its derivatives of antiparasitic drugs. **2023**, 108359
- 4 Chalcones and Gastrointestinal Cancers: Experimental Evidence. **2023**, 24, 5964
- 3 Suberoylanilide Hydroxamic Acid Ameliorates Pain Sensitization in Central Neuropathic Pain After Spinal Cord Injury via the HDAC5/NEDD4/SCN9A Axis.
- 2 Novel (E)-3-(3-oxo-4-substituted-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis and Bioevaluation.
- 1 Targeted therapy. **2023**, 205-411